|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera.
|
31584195 |
2020 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results of the review consented to (a) summarize the available data on HER2 a predictor of recurrence and/or progression free survival on univariate and multivariate analysis, (b) explore the related issues in assessing HER2 status on these tumor samples, since they may severely impair its predictive function, and (c) report the state-of-the art of HER2 as a putative therapeutic target in BC and especially non-muscle invasive BC.
|
30463072 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further investigations are required to delineate the underlying mechanisms of combined GSTM<sup>-/-</sup> and HER2 status in bladder cancer.
|
31646988 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
About 45% of BC tissues stain for both EGFR and HER2.
|
30765854 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients' Clinical Features.
|
30296252 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conventional tumor antigens are proteins expressed on the plasma membrane of tumor cells such as EGFR, FGFR3, and ERBB2 in BCa, which can be targeted by antibodies or similar epitope-specific binding reagents.
|
30342880 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGFRBi-Ab- or HER2Bi-Ab-armed ATCs may provide a promising immunotherapy for bladder cancer.
|
29328392 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human epidermal growth factor receptor 2 (HER2) was recently reported to be involved in the development of bladder cancer.
|
30137596 |
2018 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of HER2 has been observed in various types of human malignancies including bladder cancer.
|
30066004 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate perturbations in downstream signaling pathway activation and potential resistance mechanisms to epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2) inhibition in cell line models of bladder cancer.
|
29154981 |
2018 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Altered expression of the proto-oncogene HER-2 and the two molecular markers of genetic instability MLH1 and MSH2 predicted T1 high-grade BC outcome with the higher the number of altered markers the lower the DFS and PFS.
|
29362915 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, a mutation panel of six cancer-associated genes (TSC1, FGFR3, TERT, TP53, PIK3CA and ERBB2) and an immunohistochemistry (IHC) panel containing eight bladder cancer (BC) biomarkers (EGFR, RRM1, PD-L1, BRCA1, TUBB3, ERCC, ERCC1, aberrantly glycosylated integrin α3β1 (AG) and CK5/6) were developed.
|
29941343 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.
|
27992871 |
2017 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2 immunohistochemistry (IHC) to 45 cases of bladder carcinoma, followed by fluorescent in situ hybridization (FISH) were applied.
|
28870915 |
2017 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to evaluate the overexpression of human epidermal growth factor receptor 2 (HER2) in patients with bladder cancer (BCa) and to assess its association with oncological outcomes.
|
27665356 |
2016 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Similarly, human epidermal growth factor receptor 2 is more commonly overexpressed in ductal carcinoma in situ (∼27%-56%) when compared with invasive breast cancer (∼11%-20%).FGFR3mutations in bladder cancer also decrease with tumor grade (low-grade tumors, ∼61%; high-grade, ∼11%).
|
27059373 |
2016 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer.
|
25809292 |
2015 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Encouraging preclinical results with ado-trastuzumab emtansine (T-DM1) exemplifies a new potential treatment for HER2-positive BCa along with innovative bispecific antibodies.
|
25498841 |
2015 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of the present study demonstrated that E2F transcription factor 1, which is targeted by miR-106b, and cyclin-dependent kinase inhibitor 2A (CDKN2A) and V-Erb-B2 avian erythroblastic leukemia viral oncogene homolog-2, which are targeted by miR-125b, participate in the bladder cancer pathway.
|
25955758 |
2015 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.
|
24971884 |
2014 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study analyzes the immunoexpression of EGFR and Her2/neu in 45 cases of papillary urothelial bladder carcinoma.
|
23529321 |
2013 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Blood samples from 100 consecutive UCB patients treated with radical cystectomy (RC) were investigated for the presence (CellSearch system) of CTC and their HER2 expression status (immunohistochemistry).
|
22277196 |
2012 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In AR-positive bladder cancer UMUC3 and TCC-SUP cells, dihydrotestosterone (DHT) increased the expression of EGFR and ERBB2 both in mRNA and in protein levels, and an anti-androgen hydroxyflutamide antagonized the effect of DHT.
|
21613411 |
2011 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Her2, an alias for the protein of v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian), might be an attractive therapeutic target in metastasising bladder cancer.
|
21640482 |
2011 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, the antitumor activity of gammaretroviruses carrying the IL-12 gene was enhanced through genetic modification of the envelope targeting HER2 receptor, which may be a promising strategy for bladder cancer therapy.
|
19543243 |
2010 |